1[1]Yonemura Y, Sugiyama K, Fushida S, et al. Treatment options for peritoneal dissemination with chemotherapy. In Yonemura Y(eds): Peritoneal dissemination——molecular mechanisms and the latest therapy. Maeda Shoten Co, Ltd Kanazawa, Japan, 1998:175.
2[2]Sugarbaker PH. Management of peritoneal surface malignancy: the surgeon's role. Langenbecks Arch Surg, 1999, 384: 576.
3[3]Yonemura Y, Sawa T, Kinoshita K, et al. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg, 1993, 17: 256.
4[4]Yonemura Y, Matsuki N, Sakuma H, et al. Effect of intra-arterial infusion of MMC and CDDP for gastric cancer patients with liver metastasis. Jap J Surg, 1992, 22: 253.
5[5]Ohoyama S. Nakajima S. Ishihara S, et al. FLEP therapy for advanced gastric cancer. In Miyazaki I and Yonemura Y(eds): Treatment strategies for advanced gastric cancer. Soft Science. Tokyo,1995:110.
6[6]Kern W, Brasess J, Samel S, et al. Pharmacokinetics of cisplatin and its impact on nephrotoxicity during intraoperative hyperthermic peritoneal lavage in patients with locally advanced gastric cancer. The proceedings of 2nd International Gastric Cancer Congress. 1997: 1387.
7[7]Elias D, Detroz B, Debaeme B, et al. Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia reliable and unreliable concepts. Hepatogastroenterology, 1994, 41: 207.
8[8]Yonemura Y. Hyperthermochemotherpy for the treatment of peritoneal dissemination. In Yonemura Y, et al. Contemporary approaches toward cure of gastric cancer. Kanazawa: Maeda Shoten Co. Ltd, 1996, 105.
9[9]Fujimoto S, Takahashi M, Muton T, et al.Successful intaperitoneal hyperthermic chemoperfussion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric cancer. Cancer, 1999, 85: 529.
10[10]Fujimura T, Yonemura Y, Muraoka K, et al.Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randominzed controlly study.World J Surg, 1994, 18: 150.
2Franquemont DW. Differentiation and risk assessment of gastro -in-testinal stromal tumors[J]. Am J Clin Patha,1995,103 (1): 41 -47.
3Sarlomo-Rikala M, Kovatich A, Barusevicius A,et al. CD117:asensitive marker for gastrointestinal stromal tumors that is more spe-cific than CD34[J]. Mod Pathol,1998,11 (8) :728-734.
4Nunez-Nateras R, Hurd KJ, Ferrigni EN, et al. Athermal nerve sparing robot-assisted radical prostatectomy: initial experience with microporous polysaccharide hemospheres as a topical hemo- static ggent[ J]. World J Urol,2013,31 (3) :523-527.
6Bj rses K, Holst J. Topical haemostatics in renal trauma-an evalu- ation of four different substances in an experimental setting[ J]. J Trauma,2009,66 ( 3 ) : 602 -611.
7Tschan CA, Nie M, Schwandt E, et al. Safety and efficacy of mi- croporous polysaccharide hemospheres in neurosurgery [ J ]. Neu- rosurgery,2011,69 ( 1 Suppl Operative) : ons49-63.
